Why is Aurobindo Pharma falling/rising?

As of 01-Sep, Aurobindo Pharma Ltd. is experiencing a decline in its stock price, currently at 1,025.00, which reflects a decrease of 2.7 (-0.26%). The stock has been underperforming, having fallen for the last four consecutive days, resulting in a 3.86% drop over the past week and a significant 34.88% decrease over the past year. It is also trading below all key moving averages, indicating a bearish trend. Additionally, the stock is close to its 52-week low, just 2.99% away from Rs 994.35. The company's delivery volume has decreased significantly, down by 54.92% compared to the 5-day average, suggesting falling investor participation. Despite having a low debt-to-equity ratio and attractive valuation metrics, the stock's performance has been negatively impacted by a decline in profits and poor long-term growth prospects.
In the broader market context, Aurobindo Pharma's recent performance contrasts sharply with the benchmark Sensex, which has only declined by 1.56% over the past week. The stock's year-to-date return is notably worse than the Sensex, with Aurobindo Pharma down 23.23% compared to the benchmark's gain of 2.85%. This underperformance is further highlighted by the company's flat results in June and a low debtors turnover ratio, which indicates operational inefficiencies. High institutional holdings at 41.31% suggest that knowledgeable investors are also cautious about the stock's future, contributing to the overall negative sentiment surrounding Aurobindo Pharma.